AIM2 and neoplasm: Dihlmann et al. reported that after adjusting for clinicopathological characteristics, complete lack of AIM2 expression was associated with significantly increased overall and disease-specific mortality compared to AIM2-positive tumor samples, suggesting that lack of AIM2 expression is strongly related to poor outcomes in CRC.